FDA Approves Endari for Sickle Cell Disease

It should not come as a surprise to readers of this blog- Emmaus Medical was given FDA approval for it's l-glutamine treatment for sickle cell disease.  I posted my analysis of the then-pending application back on June 17th: Good News for Sickle-Cell Patients, But How Will Emmaus Make Money? A Look at the Business Side of Pharmaceutical Policy.  As I stated then- it will be very interesting to see whether Emmaus is able to successfully complete with other sources of l-glutamine.  I look forward to Emmaus' quarterly reports.